X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NK-001 is an optimized cell therapy product composed of highly activated and alloreactive allogeneic NK cells. Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.
Lead Product(s): NK-001
Therapeutic Area: Oncology Product Name: NK-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cell-Easy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 22, 2022
Details:
Onward will assist EMERCell to scale up their patented process of activation and amplification of allogeneic NK cells which includes one of EMERCell's lead drug candidates, NK-001 and to conduct clinical investigations.
Lead Product(s): NK-001,Bispecific antibody
Therapeutic Area: Oncology Product Name: NK-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Onward Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
